Onesource Specialty Pharma Limited — Investor Meet, 12-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

OneSource Specialty Pharma has announced a board meeting to discuss the financial results for the quarter and half-year.

Q4 revenue grew 22% QoQ to INR426 Cr, and FY25 revenue rose 30% YoY to INR1,445 Cr. EBITDA doubled YoY to INR183 Cr in Q4 (43% margin) and INR467 Cr for FY25 (32% margin). Adjusted PAT turned positive at INR99 Cr versus prior-year loss. ROCE was strong at 23% for FY and 41% annualized in Q4. Net debt reduction is underway, aiming for net debt-free status in 2–3 years.

Management highlighted 50+ drug-device combination projects and capacity expansion from 40 million to 90 million units by December. FY26 will be a transition with product launches like Semaglutide amid key patent expiries, with FY27-FY28 expected steady growth targeting $400 million revenue and 38–40% EBITDA margins. Pricing is volume-driven and supported by take-or-pay contracts. Injectables are expected to retain 75–80% market share despite oral alternatives. The tone is confident, focusing on scaling DDC business and leveraging patent expiries.